Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001638599-15-000213
Filing Date
2015-08-27
Accepted
2015-08-27 21:00:09
Documents
1
Period of Report
2015-08-27

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT doc4_2162.html 4  
1 PRIMARY DOCUMENT doc4_2162.xml 4 3651
  Complete submission text file 0001638599-15-000213.txt   5357
Mailing Address 420 LEXINGTON AVENUE SUITE 350 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 350 NEW YORK NY 10170 212-584-4171
Caladrius Biosciences, Inc. (Issuer) CIK: 0000320017 (see all company filings)

EIN.: 222343568 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 8090 Services-Misc Health & Allied Services, NEC

Mailing Address C/O NEOSTEM, INC. 420 LEXINGTON AVENUE, SUITE 450 NEW YORK NY 10170
Business Address
Pecora Andrew L (Reporting) CIK: 0001510184 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33650 | Film No.: 151079903